Hypersomnia Therapeutics Market Is Driven by Rising Sleep Disorder Incidence
Hypersomnia therapeutics encompass a range of pharmaceutical agents and treatment modalities designed to alleviate excessive daytime sleepiness and improve wakefulness in patients suffering from primary and secondary hypersomnia disorders. These products include wake-promoting stimulants, selective orexin receptor agonists, and adjunctive supportive therapies that target neurological pathways governing sleep–wake cycles. The advantages of modern hypersomnia therapeutics lie in their improved safety profiles, longer half-lives for sustained efficacy, and reduced risk of rebound sleepiness. There is a growing need for Hypersomnia Therapeutics Market treatments given the limitations of off-label stimulant use and the high unmet medical demand among patients whose cognitive function, productivity, and quality of life are severely impaired by chronic hypersomnolence. Ongoing clinical trials and regulatory approvals are expanding the therapeutic toolkit, enabling physicians to personalize regimens based on disease severity, comorbidity profiles, and patient response. Increased public awareness of sleep disorders and better diagnostic criteria have further underscored the importance of effective hypersomnia interventions.


According to CoherentMI, The Global Hypersomnia Therapeutics Market is estimated to be valued at USD 349.9 Mn in 2025 and is expected to reach USD 635.5 Mn by 2032, growing at a compound annual growth rate (CAGR) of 8.9% from 2025 to 2032.

Hypersomnia Therapeutics Market
https://www.coherentmi.com/ind....ustry-reports/hypers